Seeing Eye to Eye: Case Series on Treatment Strategies for RVO

Seeing Eye to Eye: Case Series on Treatment Strategies for RVO

Seeing Eye to Eye: Case Series on Treatment Strategies for RVO
RestartResume

RVO puts patients at high risk for vision loss. Do you know the best strategies to individualize treatment and optimize vision in these patients?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Retinal vein occlusion (RVO) can lead to macular edema, which is the main cause of vision loss. Accordingly, retina specialists know that time is vision and prompt intervention is critical to good outcomes in patients with RVO.

    Join our discussion with Drs. Campochiaro, Khurana, and Scott to discover strategies to use with your patients before and during treatment and throughout maintenance to improve visual acuity while minimizing side effects.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Adrienne W. Scott, MD
    Associate Professor of Ophthalmology
    Johns Hopkins University School of Medicine
    Baltimore, MD 

    Consulting Fees: Allergan, Inc., Genentech/Roche, Novartis

    Faculty:
    Peter A. Campochiaro, MD
    Director, Retinal Cell and Molecular Laboratory
    Professor of Ophthalmology
    Wilmer Eye Institute
    Baltimore, MD 

    Consulting Fees: Aerpio Pharmaceuticals, Allegro, AsclepiX Therapeutics, Ashvattha Therapeutics, Bausch + Lomb, Clearside BIO, Exonate Ltd, Genentech/Roche, Merck & Co., Perfuse Therapeutics, Regeneron Pharmaceuticals, Wave Life Sciences
    Contracted Research: Aerpio Pharmaceuticals, Ashvattha Therapeutics, Genentech/Roche, Mallinckrodt Pharmaceuticals, Oxford Biomedica, REGENXBIO, Sanofi Genzyme
    Ownership Interest: Allegro, Graybug

    Rahul N. Khurana, MD
    Partner and Vitreoretinal Surgeon
    Northern California Retina Vitreous Associates
    Mountain View, CA 

    Consulting Fees: Aerie, Apellis, Bausch + Lomb, Merck
    Contracted Research: Apellis, Chengdu Kanghong, Graybug, REGENXBIO, Roche

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Emily Chew, MD, has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Stephanie Wenick has nothing to disclose. 
  • Learning Objective

    After participating in this educational activity, participants should be better able to:

    • Individualize treatment strategies to improve visual acuity while minimizing side effects in patients with RVO
  • Target Audience

    This activity is designed to meet the educational needs of retina specialists.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the U.S. Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free